MA31997B1 - Nouveaux derives de l'insuline presentant un profil d'action extremement retarde - Google Patents
Nouveaux derives de l'insuline presentant un profil d'action extremement retardeInfo
- Publication number
- MA31997B1 MA31997B1 MA32984A MA32984A MA31997B1 MA 31997 B1 MA31997 B1 MA 31997B1 MA 32984 A MA32984 A MA 32984A MA 32984 A MA32984 A MA 32984A MA 31997 B1 MA31997 B1 MA 31997B1
- Authority
- MA
- Morocco
- Prior art keywords
- insulin derivatives
- delayed action
- action profile
- novel insulin
- extremely delayed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne de nouveaux analogues d'insuline à profil temporel/d'action basal, caractérisés par une addition et/ou une substitution de radicaux aminoacide chargés négativement et positivement, et par une amidation du groupe carboxy c-terminal de la chaîne b, et de l'histidine en position 8 de la chaîne a de l'insuline. L'invention concerne également la fabrication et l'utilisation de ces analogues d'insuline.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008003566A DE102008003566A1 (de) | 2008-01-09 | 2008-01-09 | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
US4466208P | 2008-04-14 | 2008-04-14 | |
DE200810025007 DE102008025007A1 (de) | 2008-05-24 | 2008-05-24 | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
PCT/EP2009/000018 WO2009087082A2 (fr) | 2008-01-09 | 2009-01-06 | Nouveaux dérivés d'insuline à profil temporel/d'action extrêmement retardé |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31997B1 true MA31997B1 (fr) | 2011-01-03 |
Family
ID=40473425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32984A MA31997B1 (fr) | 2008-01-09 | 2010-07-05 | Nouveaux derives de l'insuline presentant un profil d'action extremement retarde |
Country Status (21)
Country | Link |
---|---|
US (1) | US8633156B2 (fr) |
EP (1) | EP2229406B1 (fr) |
JP (1) | JP5695909B2 (fr) |
KR (1) | KR20100111683A (fr) |
CN (1) | CN101970476B (fr) |
AR (1) | AR070119A1 (fr) |
AU (1) | AU2009203810B2 (fr) |
BR (1) | BRPI0907119A2 (fr) |
CA (1) | CA2711752A1 (fr) |
CL (1) | CL2009000018A1 (fr) |
CO (1) | CO6290770A2 (fr) |
HK (1) | HK1148542A1 (fr) |
IL (1) | IL206843A0 (fr) |
MA (1) | MA31997B1 (fr) |
NZ (1) | NZ586589A (fr) |
PA (1) | PA8811501A1 (fr) |
PE (1) | PE20091305A1 (fr) |
TW (1) | TWI433681B (fr) |
UY (1) | UY31597A1 (fr) |
WO (1) | WO2009087082A2 (fr) |
ZA (1) | ZA201003927B (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005046113A1 (de) * | 2005-09-27 | 2007-03-29 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen |
KR20100111682A (ko) | 2008-01-09 | 2010-10-15 | 사노피-아벤티스 도이칠란트 게엠베하 | 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체 |
KR101820024B1 (ko) | 2008-10-17 | 2018-01-18 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린과 glp-1 효능제의 병용물 |
BRPI0823377A2 (pt) | 2008-12-15 | 2016-09-27 | Zealand Pharma As | análogos de glucagon |
MX2011006313A (es) | 2008-12-15 | 2011-09-27 | Zealand Pharma As | Analogos de glucagon. |
BRPI0823379A2 (pt) | 2008-12-15 | 2015-07-14 | Zealand Pharma As | Análogos de glucagon |
DK2370460T3 (da) | 2008-12-15 | 2014-08-04 | Zealand Pharma As | Glucagon analoger |
DK2454282T3 (en) | 2009-07-13 | 2015-05-04 | Zealand Pharma As | acetylated glucagonanaloger |
ES2534191T3 (es) | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
HUE037735T2 (hu) | 2009-11-13 | 2018-09-28 | Sanofi Aventis Deutschland | DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény |
AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
EP2585482B1 (fr) | 2010-06-24 | 2019-03-27 | Zealand Pharma A/S | Analogues de glucagon |
EP3366304B1 (fr) | 2010-06-24 | 2020-05-13 | Boehringer Ingelheim International GmbH | Traitement du diabète |
BR112013004756B1 (pt) | 2010-08-30 | 2020-04-28 | Sanofi Aventis Deutschland | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 |
US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
EP2665487A1 (fr) | 2011-01-20 | 2013-11-27 | Zealand Pharma A/S | Combinaison d'analogues du glucagon acylé à des analogues d'insuline |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
RU2650616C2 (ru) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
KR102184241B1 (ko) | 2012-05-03 | 2020-12-01 | 질랜드 파마 에이/에스 | Gip-glp-1 이원 작용제 화합물 및 방법 |
CN104662038B (zh) | 2012-07-23 | 2018-11-06 | 西兰制药公司 | 胰高血糖素类似物 |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
KR102569036B1 (ko) | 2013-10-17 | 2023-08-23 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
CN105849122B (zh) | 2013-11-06 | 2021-04-30 | 西兰制药公司 | Gip-glp-1双重激动剂化合物及方法 |
US10131702B2 (en) | 2013-11-06 | 2018-11-20 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
US9895424B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
US9839692B2 (en) | 2014-01-09 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
SG11201604706TA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart |
MX369656B (es) | 2014-01-20 | 2019-11-15 | Hanmi Pharm Ind Co Ltd | Insulina de accion prolongada y uso de la misma. |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
RU2716985C2 (ru) | 2014-10-29 | 2020-03-17 | Зилэнд Фарма А/С | Соединения-агонисты gip и способы |
JP6970615B2 (ja) | 2014-12-12 | 2021-11-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン/リキシセナチド固定比処方 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
RU2735762C2 (ru) | 2015-04-16 | 2020-11-06 | Зилэнд Фарма А/С | Ацилированный аналог глюкагона, его применение и способы получения |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
KR20180033105A (ko) | 2016-09-23 | 2018-04-02 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도 |
EP3604328A4 (fr) | 2017-03-23 | 2021-01-06 | Hanmi Pharm. Co., Ltd. | Complexe d'analogue à l'insuline à affinité réduite pour le récepteur de l'insuline et son utilisation |
CN110615836B (zh) * | 2018-06-20 | 2022-09-13 | 鲁南制药集团股份有限公司 | 一种利拉鲁肽的固相合成方法 |
CN115702880B (zh) * | 2021-08-12 | 2023-11-03 | 山东新时代药业有限公司 | 一种重组甘精胰岛素注射液及其制备工艺 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK113585D0 (da) * | 1985-03-12 | 1985-03-12 | Novo Industri As | Nye peptider |
US5008241A (en) * | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
DK347086D0 (da) * | 1986-07-21 | 1986-07-21 | Novo Industri As | Novel peptides |
NZ223630A (en) | 1987-02-25 | 1989-11-28 | Novo Industri As | Insulin derivative and pharmaceutical compositions |
DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
DE3837825A1 (de) * | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
US5225323A (en) * | 1988-11-21 | 1993-07-06 | Baylor College Of Medicine | Human high-affinity neurotransmitter uptake system |
DK134189D0 (da) * | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
GR1005153B (el) | 1989-08-29 | 2006-03-13 | The General Hospital Corporation | Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους. |
DK10191D0 (da) | 1991-01-22 | 1991-01-22 | Novo Nordisk As | Hidtil ukendte peptider |
DE4405388A1 (de) | 1994-02-19 | 1995-08-24 | Hoechst Ag | Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen |
WO1996034882A1 (fr) | 1995-05-05 | 1996-11-07 | Eli Lilly And Company | Insuline monocatenaire a bioactivite elevee |
CA2468374C (fr) | 1996-08-30 | 2010-12-21 | Novo-Nordisk A/S | Derives de glp-1 |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
US6444641B1 (en) * | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
JP2001521006A (ja) | 1997-10-24 | 2001-11-06 | イーライ・リリー・アンド・カンパニー | 不溶性インシュリン組成物 |
US6100378A (en) | 1998-03-12 | 2000-08-08 | Biopore, Inc. | Enhancement of the pro-fertility action of a molecule involved in a sperm-egg binding |
EP1076066A1 (fr) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides abaissant le taux de glucose sanguin |
DE19947456A1 (de) * | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
DE10108212A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände |
DE10108211A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen |
ATE443082T1 (de) * | 2001-04-02 | 2009-10-15 | Novo Nordisk As | Insulinvorstufen und verfahren zu deren herstellung |
KR20040070237A (ko) * | 2001-12-20 | 2004-08-06 | 일라이 릴리 앤드 캄파니 | 연장된 작용 시간을 갖는 인슐린 분자 |
US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
WO2004005342A1 (fr) | 2002-07-04 | 2004-01-15 | Zealand Pharma A/S | Glp-1 et methodes de traitement du diabete |
US7544657B2 (en) * | 2002-10-02 | 2009-06-09 | Zealand Pharma A/S | Stabilized Exendin-4 compounds |
BRPI0409600A (pt) | 2003-04-29 | 2006-04-18 | Lilly Co Eli | análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina |
CN1780854A (zh) * | 2003-04-29 | 2006-05-31 | 伊莱利利公司 | 具有延长时间作用的胰岛素类似物 |
EP1771573A4 (fr) * | 2004-07-21 | 2009-02-18 | Ambrx Inc | Polypeptides biosynthetiques obtenus a partir d'acides amines codes par voie non naturelle |
EP1791554A2 (fr) | 2004-09-17 | 2007-06-06 | Novo Nordisk A/S | Compositions pharmaceutiques contenant de l'insuline et un peptide insulinotropique |
DE102004058306A1 (de) | 2004-12-01 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden |
BRPI0616054B8 (pt) | 2005-09-14 | 2021-05-25 | Sanofi Aventis Deutschland | processo para a preparação de insulina, um análogo de insulina ou um derivado de insulina, tripsina porcina, método para sua produção, dna e vetor |
WO2007081824A2 (fr) * | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Protéines résistantes à la fibrillation |
KR101374851B1 (ko) | 2006-01-10 | 2014-03-14 | 톰슨 라이센싱 | 4:4:4 코딩의 병렬 구현을 위한 방법 및 장치 |
KR20100111682A (ko) | 2008-01-09 | 2010-10-15 | 사노피-아벤티스 도이칠란트 게엠베하 | 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체 |
-
2009
- 2009-01-06 BR BRPI0907119-9A patent/BRPI0907119A2/pt not_active Application Discontinuation
- 2009-01-06 AU AU2009203810A patent/AU2009203810B2/en not_active Ceased
- 2009-01-06 JP JP2010541744A patent/JP5695909B2/ja not_active Expired - Fee Related
- 2009-01-06 CN CN200980101942.6A patent/CN101970476B/zh not_active Expired - Fee Related
- 2009-01-06 KR KR1020107014964A patent/KR20100111683A/ko not_active Application Discontinuation
- 2009-01-06 EP EP09700949.2A patent/EP2229406B1/fr active Active
- 2009-01-06 WO PCT/EP2009/000018 patent/WO2009087082A2/fr active Application Filing
- 2009-01-06 CA CA2711752A patent/CA2711752A1/fr not_active Abandoned
- 2009-01-06 NZ NZ586589A patent/NZ586589A/en not_active IP Right Cessation
- 2009-01-07 AR ARP090100036A patent/AR070119A1/es unknown
- 2009-01-07 PE PE2009000010A patent/PE20091305A1/es not_active Application Discontinuation
- 2009-01-07 TW TW098100283A patent/TWI433681B/zh not_active IP Right Cessation
- 2009-01-07 CL CL2009000018A patent/CL2009000018A1/es unknown
- 2009-01-07 UY UY031597A patent/UY31597A1/es not_active Application Discontinuation
- 2009-01-07 PA PA20098811501A patent/PA8811501A1/es unknown
-
2010
- 2010-06-02 ZA ZA2010/03927A patent/ZA201003927B/en unknown
- 2010-06-22 US US12/820,727 patent/US8633156B2/en not_active Expired - Fee Related
- 2010-06-25 CO CO10076884A patent/CO6290770A2/es not_active Application Discontinuation
- 2010-07-05 MA MA32984A patent/MA31997B1/fr unknown
- 2010-07-06 IL IL206843A patent/IL206843A0/en unknown
-
2011
- 2011-03-17 HK HK11102681.7A patent/HK1148542A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2009087082A3 (fr) | 2009-09-24 |
IL206843A0 (en) | 2010-12-30 |
HK1148542A1 (en) | 2011-09-09 |
TWI433681B (zh) | 2014-04-11 |
EP2229406B1 (fr) | 2015-04-22 |
NZ586589A (en) | 2012-04-27 |
UY31597A1 (es) | 2009-08-31 |
CN101970476A (zh) | 2011-02-09 |
EP2229406A2 (fr) | 2010-09-22 |
ZA201003927B (en) | 2011-04-28 |
JP2011509269A (ja) | 2011-03-24 |
AU2009203810B2 (en) | 2013-07-25 |
PA8811501A1 (es) | 2009-09-17 |
WO2009087082A2 (fr) | 2009-07-16 |
JP5695909B2 (ja) | 2015-04-08 |
CN101970476B (zh) | 2014-08-27 |
AU2009203810A1 (en) | 2009-07-16 |
TW200942257A (en) | 2009-10-16 |
US8633156B2 (en) | 2014-01-21 |
CO6290770A2 (es) | 2011-06-20 |
CL2009000018A1 (es) | 2009-06-05 |
BRPI0907119A2 (pt) | 2015-07-14 |
KR20100111683A (ko) | 2010-10-15 |
PE20091305A1 (es) | 2009-09-26 |
US20110173722A1 (en) | 2011-07-14 |
AR070119A1 (es) | 2010-03-17 |
CA2711752A1 (fr) | 2009-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31997B1 (fr) | Nouveaux derives de l'insuline presentant un profil d'action extremement retarde | |
TN2010000298A1 (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
UA103015C2 (ru) | Новые производные инсулина с чрезвычайно замедленным профилем время/действие | |
BR112014000466A2 (pt) | polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos | |
MY192981A (en) | Cyclosporine analogue molecules modified at amino acid 1 and 3 | |
EA201690623A1 (ru) | Простациклиновые соединения, композиции и способы их использования | |
NO20071419L (no) | Polypeptidvarianter med endret effektorfunksjon | |
GT201300295A (es) | "composiciones que contienen, metodos que involucran, y usos de derivados de dolastatina unidos a aminoacidos no naturales" | |
WO2009155555A3 (fr) | Mise à jour de définitions de logiciel malveillant en continu | |
CY1110397T1 (el) | Πολυπεπτιδιο που εχει βελτιωμενη δραστικοτητα αποαμινασης κυτοσινης | |
EA201491155A1 (ru) | Новые мутантные про-нрф и их применение для получения бета-нрф | |
BRPI0814971A8 (pt) | Proteína | |
EA201201608A1 (ru) | Солнцезащитная композиция | |
BR112012011467A2 (pt) | forma glicosilada de análogo ao glp-1 antigênico. | |
EA201490790A1 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 | |
EA201600088A1 (ru) | Парентеральное введение тапентадола | |
NZ703093A (en) | Purification of iduronate-2-sulfatase | |
BR112012017532A2 (pt) | "método para determinar um polipeptídeo com uma sequência de aminoácidos mutante, para produzir um poliptedo e uma imunoglobulina" | |
MX2013008699A (es) | Compuestos para reducir la produccion de beta-amiloide. | |
IN2014DN09367A (fr) | ||
EA201491225A1 (ru) | Шина, содержащая композицию, по существу, не включающую гуанидиновое производное и содержащую первичный амин | |
BR112015015182A2 (pt) | polipeptídeos do fator vii de ação curta | |
UA114592C2 (uk) | Пептид nd2 та спосіб лікування неврологічного захворювання | |
EP2593546A4 (fr) | Purification par affinité d'arn dans des conditions d'origine sur la base de l'interaction lambda boîteb/n peptide | |
IN2014CN02399A (fr) |